<DOC>
	<DOC>NCT01871428</DOC>
	<brief_summary>This multicenter, randomized, double-blind, placebo-controlled study will evaluate the efficacy, safety and tolerability of aleglitazar monotherapy in patients with Type 2 diabetes mellitus who are drug-naïve to anti-hyperglycemic therapy. Patients will be randomized to receive either aleglitazar 150 mcg orally daily or placebo for 26 weeks.</brief_summary>
	<brief_title>A Study of Aleglitazar in Monotherapy in Patients With Type 2 Diabetes Mellitus Who Are Drug-Naïve to Anti-Hyperglycemic Therapy</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<criteria>Adult patient, &gt;/= 18 years of age Diagnosis of Type 2 diabetes mellitus within 12 months prior to screening Drugnaïve (defined as no antihyperglycemic medication for at least 12 weeks prior to screening and for not longer than 3 consecutive months at any time in the past) HbA1c &gt;/= 7% and &lt;/= 9.5% at screening or within 4 weeks prior to screening and at prerandomization visit Fasting plasma glucose &lt;/= 13.3 mmol/L (&lt;/= 240 mg/dL) at prerandomization visit Agreement to maintain diet and exercise habits implemented during the runin phase during the full course of the study Pregnant women, women intending to become pregnant during the study period, currently lactating women, or women of childbearing potential not using highly effective, medically approved birth control methods Diagnosis or history of: 1. Type 1 diabetes mellitus, diabetes resulting from pancreatic injury, or secondary forms of diabetes 2. Acute metabolic diabetic complications such as ketoacidosis or hyperosmolar coma within the past 6 months Any previous treatment with thiazolidinedione or with a dual peroxisome proliferator activated receptor (PPAR) agonist Any body weight lowering or lipoproteinmodifying therapy (e.g. fibrates) within 12 weeks prior to screening with the exception of stable (&gt;= 1 month) statin therapy Prior intolerance to fibrate Triglycerides (fasting) &gt; 4.5 mmol/L (&gt; 400 mg/dL) at screening or within 4 weeks prior to screening Clinically apparent liver disease Anemia at or within 4 weeks prior to screening Inadequate renal function Symptomatic congestive heart failure New York Heart Association (NYHA) Class IIIV at screening Myocardial infarction, acute coronary syndrome or transient ischemic attack/stroke within 6 months prior to screening visit Known macular edema at screening or prior to screening visit Diagnosed and/or treated malignancy (except for basal cell skin cancer, in situ carcinoma of the cervix, or in situ prostate cancer) within the past 5 years Uncontrolled hypertension History of active substance abuse (including alcohol) within the past 2 years</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>